Analysis of Various Types of Glomerulonephritis with Crescents at a Single Center

Table 2

Clinical and pathological findings in type II and type III rapid progressive glomerulonephritis at the time of renal biopsy.

	Type II (n = 149)	Type III (n = 47)	value
Clinical findings
Age (years)	34 (26–45)	64 (54–70.5)	<0.0001
Sex (male/female)	66/83 (M: 44%)	18/30 (M: 38%)	<0.0001
Mean arterial pressure (mmHg)	92.3 (84.7–100)	96 (82.7–105.8)	0.2065
Body mass index	21.5 (19.8–23.5)	21.6 (19.9–24.3)	0.6903
Total serum protein (g/dL)	6.3 (5.7–6.9)	6.6 (6.2–7.2)	0.0238
Serum albumin (g/dL)	3.7 (3.1–4.1)	3.2 (2.6–4)	0.0438
Blood urea nitrogen (mg/dL)	14.5 (12.1–19.4)	26.7 (18.2–43.2)	<0.0001
Serum creatinine (mg/dL)	0.79 (0.67–1.02)	1.71 (1.03–2.76)	<0.0001
Estimated GFR (mL/min/1.73 m^2)	75.8 (59.1–98.0)	25 (16.8–42.9)	<0.0001
Urine protein (g/g creatinine)	1.33 (0.71–2.73)	1.54 (0.74–2.75)	0.7207
Urine red blood cell count (counts/HPF)	20 (10–50)	20 (10–30)	0.5211
IgG (mg/dL)	1037 (807–1323)	1338 (1047–1626)	0.0006
IgA (mg/dL)	267 (198–366)	215 (166–281)	0.0037
IgM (mg/dL)	106 (79–149)	89 (58–115)	0.0269
CH50 (mg/dL)	39.5 (32.1–47.8)	51.3 (43.6–59.0)	<0.0001
C3 (mg/dL)	91.5 (72.9–109.5)	106.6 (95.8–121)	<0.0001
C4 (mg/dL)	21.5 (15.3–26.9)	26.9 (22.0–34.1)	<0.0001
Complications (%)
Diabetes mellitus	9 (6)	5 (10.4)	0.2912
Hypertension	40 (26.8)	20 (41.7)	0.0086
Dyslipidemia	39 (26.2)	24 (50)	0.5206
Hyperuricemia	15 (10.1)	9 (18.8)	0.0422
Treatment (%)
Antiplatelet drug	107 (72)	16 (33.3)	0.0002
ACEI/ARB	74 (50)	25 (52.1)	0.3300
Pathological findings
Percentage of global glomerulosclerosis (%)	10.0 (0–22.2)	27.8 (6.7–38.4)	<0.0001
Percentage of crescents; (Cellular/fibrocellular/fibrous) (%)	15.9 (9.1–27.3)	28 (20.6–51.7)	<0.0001
Tubulointerstitial lesions^a (0/1/2/3)	34/7732/5	9/11/11/12	0.0001
Arteriosclerosis^b (0/1/2/3)	85/2924/5	16/13/11/4	0.0094
Arteriolar sclerosis^b (0/1/2/3)	78/43/24/3	16/19/8/1	0.1548
Percentage of normal glomeruli (%)	67.0 (49.0–80.5)	34.5 (21.0–54.5)	<0.0001

GFR, glomerular filtration rate, HPF, high-power field; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker. ^aTubular atrophy and interstitial fibrosis score: <5%, 0; 5 ≤ lesion < 20, 1; 20 ≤ lesion < 50, 2;  ≥ 50, 3. ^bArteriosclerosis and arteriolosclerosis score: none or low, 0; middle, 1; high, 2; and very high, 3.